|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 919 DKK | -5.26% |
|
-5.86% | +31.64% |
| 05:11pm | European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading | MT |
| 01:48pm | Novo Nordisk to Update Weight Loss Drugs Labels Over EMA's Safety Recommendation | MT |
COPENHAGEN/LONDON, Jan 31 (Reuters) - Novo Nordisk on Wednesday posted fourth-quarter operating profit above expectations as it forecast another year of double-digit record sales growth due to its wildly popular Wegovy weight-loss drug.
The Danish company said it expects sales growth this year between 16% and 25%, as demand soars for Wegovy and diabetes drug Ozempic, which contains the same active ingredient.
(Reporting by Jacob Gronholt-Pedersen and Maggie Fick Editing by Josephine Mason)
| 1st Jan change | Capi. | |
|---|---|---|
| +31.64% | 63TCr | |
| +56.52% | 85TCr | |
| +0.19% | 36TCr | |
| +15.35% | 32TCr | |
| +12.80% | 30TCr | |
| +15.51% | 24TCr | |
| +16.72% | 23TCr | |
| +16.20% | 18TCr | |
| +4.15% | 17TCr | |
| +2.52% | 13TCr |
NOVO NORDISK A/S 
